Buchumschlag

PARP inhibition in BRCA2-mutated prostate cancer

Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant explora...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Nientiedt, Cathleen (VerfasserIn) , Tolstov, Yanis (VerfasserIn) , Volckmar, Anna-Lena (VerfasserIn) , Endris, Volker (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Hohenfellner, Markus (VerfasserIn) , Grüllich, Carsten (VerfasserIn) , Duensing, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: 2017
In: Annals of oncology
Year: 2016, Jahrgang: 28, Heft: 1, Pages: 189-191
ISSN:1569-8041
DOI:10.1093/annonc/mdw445
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw445
Verlag, Volltext: https://academic.oup.com/annonc/article/28/1/189/2669812
Volltext
Verfasserangaben:C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sültmann, A. Stenzinger, M. Hohenfellner, C. Grüllich, S. Duensing
Beschreibung
Zusammenfassung:Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant exploration. We report here the remarkable clinical course of a patient with a germline BRCA2 mutation treated with the PARP inhibitor olaparib.
Beschreibung:Published online 29 September 2016
Gesehen am 19.07.2018
Beschreibung:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw445

Ähnliche Einträge